MacBeath Gavin 4

What Happened

• Gavin MacBeath, CEO of TScan Therapeutics (TCRX), received a derivative award of 1,165,000 shares on 2026-01-20. The Form 4 lists the acquisition at $0.00 per share (derivative), i.e., a grant/award rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-01-20; filing date: 2026-01-22 (timely).
• Reported terms: 1,165,000 shares acquired @ $0.00 (derivative award).
• Shares owned after transaction: not specified in the provided excerpt of the Form 4.
• Footnote: The award is an option that vests 25% on the one-year anniversary of Jan 20, 2026, then vests in equal monthly installments over the next 36 months, subject to continued service.
• Filing status: No late-filing indication in the provided data.

Context

• This is a compensation-related grant (derivative award/options) and not a market purchase or sale. Such grants are common for executives and reflect employment/retention incentives; they do not by themselves indicate immediate buying or selling of stock. The award becomes exercisable over time per the vesting schedule; there is no indication in this filing that any shares were exercised or sold.